All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Prof. Andrés Ferreri, from the San Raffaele Scientific Institute, Milan, IT, on the use of clarithromycin in Extranodal Marginal Zone Lymphoma:
Extranodal Marginal Zone Lymphoma and the use of clarithromycin
SOHO 2019 | How could patients benefit from "point-of-care" CAR T-cell therapy?
At SOHO 2019, Dr Boro Dropulic spoke to the Lymphoma Hub about how patients benefit from "point-of-care" CAR T-cell therapy: lower cost, fewer logistical problems and...
EHA 2019 | Anti-CD47 antibody, HU5F9-G4, with rituximab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and indolent non-Hodgkin lymphoma (iNHL)
The results of a phase Ib/II clinical trial using HU5F9-G4 (5F9) and rituximab combination...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox